Examkin

Soru

Zorluk: ZorEnd-of-Life and Palliative Care

A 62-year-old female with stage IV renal cell carcinoma is brought to the emergency department by her husband due to worsening pain and confusion over the past three days. The patient has known widespread bone metastases. Her home pain regimen includes high-dose extended-release morphine and frequent doses of immediate-release morphine, which were recently escalated due to inadequately controlled back pain. On arrival, the patient is agitated and complains of severe pain "all over my body." The husband notes she has been having sudden, involuntary jerking movements of her arms and legs. Vital signs show a blood pressure of 138/85 mm Hg, a heart rate of 102/min, a respiratory rate of 16/min, and an oxygen saturation of 96% on room air. Physical examination reveals diffuse hyperalgesia; she withdraws and cries out when the physician gently rests a stethoscope on her chest. Neurologic examination shows bilateral myoclonus but no focal motor or sensory weakness. Laboratory studies reveal a serum creatinine of 2.1 mg/dL (baseline 1.1 mg/dL). Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Administer intravenous naloxone
  2. B
    Increase the dose of the current opioid medication
  3. Rotate to a different opioid analgesic and administer intravenous fluidsCevap
  4. D
    Order emergent magnetic resonance imaging of the complete spine
  5. E
    Initiate palliative sedation with a continuous midazolam infusion

Cevap

Rotate to a different opioid analgesic and administer intravenous fluids
The correct answer is to rotate to a different opioid analgesic and administer intravenous fluids. This patient is exhibiting classic signs of opioid-induced neurotoxicity (OIN), which encompasses opioid-induced hyperalgesia (OIH), myoclonus, and delirium. Morphine is metabolized in the liver to morphine-6-glucuronide (analgesic) and morphine-3-glucuronide (M3G, which is neuroexcitatory). Both metabolites are renally excreted. In the setting of acute kidney injury, M3G accumulates, leading to central nervous system excitation. OIH is characterized by a paradoxical increase in pain sensitivity, often diffuse and accompanied by allodynia (experiencing pain from non-noxious stimuli, such as a stethoscope resting lightly on the chest). The definitive management of OIN involves lowering the total opioid dose, rotating to an alternative opioid with different metabolic pathways (such as fentanyl, methadone, or buprenorphine), and aggressively hydrating the patient to facilitate renal clearance of the accumulated toxic metabolites.

Adım Adım Çözüm

1
Analyze the patient's new-onset symptoms.
The patient developed diffuse pain (hyperalgesia), myoclonus, and confusion following a recent morphine dose escalation in the setting of acute kidney injury.
Identifying the constellation of symptoms alongside recent changes in medication or organ function is crucial for diagnosing pharmacologic adverse events.
2
Differentiate disease progression from medication toxicity.
Unlike the patient's localized bone metastases pain, the current pain is diffuse and provoked by non-noxious stimuli (allodynia), indicating central nervous system sensitization.
Distinguishing between worsening cancer pain and opioid-induced hyperalgesia determines whether the opioid dose should be increased or decreased.
3
Determine the underlying pathophysiology.
The accumulation of morphine-3-glucuronide (M3G), a neuroexcitatory metabolite of morphine, due to impaired renal excretion has caused opioid-induced neurotoxicity (OIN).
Understanding the pharmacokinetic clearance of specific opioids guides the choice of corrective interventions.
4
Select the appropriate management strategy.
The correct intervention is to reduce the opioid dose, rotate to an opioid with a different metabolic pathway (e.g., fentanyl, methadone), and administer intravenous fluids.
Opioid rotation restores analgesia while preventing further accumulation of the offending metabolite, and hydration facilitates its renal clearance.

Anahtar Kavram

Opioid-induced neurotoxicity (OIN) and hyperalgesia present with diffuse allodynia, myoclonus, and delirium, often triggered by dose escalations or renal failure. Management requires opioid rotation, dose reduction, and aggressive hydration.
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru